Table 4.

Summary of the multivariate analysis (MVA) with logistic regression for objective response rate (ORR)

Variable (comparator)	Pembrolizumab cohort—MVA ORR						Chemotherapy cohort—MVA ORR
	Coeff.	SE	aOR (95% CI); p value	Coeff.	SE	aOR (95% CI); p value	Coeff.	SE	aOR (95% CI); p value	Coeff.	SE	aOR (95% CI); p value
BMI (normal weight)
Underweight	0.646	0.401	0.52 (0.23–1.15); p=0.1067				0.717	0.591	0.49 (0.15–1.56); p=0.2251
Overweight	0.134	0.169	0.87 (0.62–1.21); p=0.4281				0.535	0.231	0.59 (0.37–0.92); p=0.0208
Obese	−0.474	0.224	1.61 (1.04–2.50); p=0.0348				0.080	0.318	0.93 (0.49–1.72); p=0.8011
ΔBMI
≥1.4% vs <1.4%	–	–	–	1.020	0.189	2.78 (1.92–4.16); p<0.0001	–	–	–	0.869	0.230	2.38 (1.51–3.70); p=0.0002
Gender
Male vs female	0.001	0.156	0.99 (0.73–1.35); p=0.9917	−0.099	0.170	1.10 (0.79–1.54); p=0.5579	0.189	0.225	0.82 (0.53–1.28); p=0.3999	0.209	0.227	0.81 (0.51–1.26); p=0.3568
Age
Elderly vs non-elderly	0.049	0.146	0.95 (0.71–1.26); p=0.7380	0.061	0.159	0.94 (0.69–1.29); p=0.7022	0.541	0.214	0.58 (0.38–1.28); p=0.0117	0.530	0.215	0.59 (0.38–0.89); p=0.0140
CNS metastases
Yes vs no	0.063	0.190	0.93 (0.64–1.36); p=0.7370	0.077	0.208	0.92 (0.61–1.39); p=0.7108	0.006	0.285	0.99 (0.57–1.74); p=0.9824	0.029	0.287	0.97 (0.55–1.70); p=0.9190
Bone metastases
Yes vs no	0.675	0.162	0.51 (0.37–0.69); p<0.0001	0.639	0.175	0.52 (0.37–0.74); p=0.0003	0.637	0.238	0.52 (0.33–0.84); p=0.0077	0.542	0.242	0.58 (0.36–0.93); p=0.0256
Liver metastases
Yes vs no	0.363	0.213	0.69 (0.45–1.05); p=0.0882	0.290	0.232	0.74 (0.47–1.18); p=0.2123	0.636	0.321	0.53 (0.28–0.99); p=0.0478	0.674	0.324	0.51 (0.25–0.96); p=0.0380
ECOG-PS
≥2 vs (0–1)	0.967	0.221	0.38 (0.24–0.58); p<0.0001	0.705	0.243	0.49 (0.31–0.79); p=0.0038	0.144	0.410	0.86 (0.38–1.93); p=0.7249	0.286	0.421	0.75 (0.32–1.71); p=0.4962
Nagelkerke R2	0.0922			0.1115			0.1348			0.1129

aOR, adjusted OR; BMI, body mass index; CNS, central nervous system; ECOG-PS, Easter Cooperative Oncology Group—Performance Status.